| mRNA |
S-Trityl-L-cysteine |
GDSC1000 |
pan-cancer |
AAC |
-0.16 |
0.007 |
| mRNA |
navitoclax:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.007 |
| mRNA |
TGX221 |
GDSC1000 |
pan-cancer |
AAC |
-0.15 |
0.007 |
| mRNA |
thalidomide |
CTRPv2 |
pan-cancer |
AAC |
0.16 |
0.008 |
| mRNA |
Bexarotene |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.008 |
| mRNA |
NVP-BEZ235 |
GDSC1000 |
pan-cancer |
AAC |
-0.099 |
0.008 |
| mRNA |
CCT007093 |
GDSC1000 |
pan-cancer |
AAC |
0.094 |
0.01 |
| mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.095 |
0.01 |
| mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.096 |
0.01 |
| mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.091 |
0.01 |